DK3301447T3 - Anti-tumorrespons til modificerede selvepitoper - Google Patents

Anti-tumorrespons til modificerede selvepitoper Download PDF

Info

Publication number
DK3301447T3
DK3301447T3 DK17194252.7T DK17194252T DK3301447T3 DK 3301447 T3 DK3301447 T3 DK 3301447T3 DK 17194252 T DK17194252 T DK 17194252T DK 3301447 T3 DK3301447 T3 DK 3301447T3
Authority
DK
Denmark
Prior art keywords
pitopes
tumor response
modified self
self
modified
Prior art date
Application number
DK17194252.7T
Other languages
English (en)
Inventor
Linda Gillian Durrant
Victoria Anne Brentville
Rachel Louise Metheringham
Original Assignee
Scancell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scancell Ltd filed Critical Scancell Ltd
Application granted granted Critical
Publication of DK3301447T3 publication Critical patent/DK3301447T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
DK17194252.7T 2012-08-07 2013-08-07 Anti-tumorrespons til modificerede selvepitoper DK3301447T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1214007.5A GB201214007D0 (en) 2012-08-07 2012-08-07 Anti-tumour immune responses to modified self-epitopes
EP13750368.6A EP2883054B1 (en) 2012-08-07 2013-08-07 Anti-tumour response to modified self-epitopes

Publications (1)

Publication Number Publication Date
DK3301447T3 true DK3301447T3 (da) 2021-03-08

Family

ID=46934958

Family Applications (3)

Application Number Title Priority Date Filing Date
DK13750368.6T DK2883054T3 (da) 2012-08-07 2013-08-07 Antitumor-respons på modificerede selv-epitoper
DK17194251.9T DK3287787T3 (da) 2012-08-07 2013-08-07 Anti-tumorrespons til modificerede selv-epitoper
DK17194252.7T DK3301447T3 (da) 2012-08-07 2013-08-07 Anti-tumorrespons til modificerede selvepitoper

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK13750368.6T DK2883054T3 (da) 2012-08-07 2013-08-07 Antitumor-respons på modificerede selv-epitoper
DK17194251.9T DK3287787T3 (da) 2012-08-07 2013-08-07 Anti-tumorrespons til modificerede selv-epitoper

Country Status (16)

Country Link
US (4) US10233220B2 (da)
EP (3) EP2883054B1 (da)
JP (2) JP6490581B2 (da)
KR (1) KR102203096B1 (da)
CN (2) CN104823054B (da)
AU (1) AU2013301341B2 (da)
BR (1) BR112015002574A8 (da)
DK (3) DK2883054T3 (da)
ES (3) ES2833962T3 (da)
GB (1) GB201214007D0 (da)
IN (1) IN2014DN10629A (da)
PL (2) PL3301447T3 (da)
PT (3) PT2883054T (da)
SG (2) SG11201407804RA (da)
WO (1) WO2014023957A2 (da)
ZA (1) ZA201409095B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CN113637076A (zh) * 2014-05-05 2021-11-12 诺维奥Th私人有限公司 类风湿性关节炎的血清学诊断方法
CN104360070B (zh) * 2014-11-28 2017-02-22 山东新创生物科技有限公司 肽基精氨酸脱亚胺酶2在制备肿瘤临床血液诊断试剂中的应用
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
WO2018046648A1 (en) * 2016-09-08 2018-03-15 Katholieke Universiteit Leuven Citrullinated peptides for diagnosis or treatment of diabetes
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
GB202005779D0 (en) * 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy
CN114404570B (zh) * 2022-01-20 2023-05-30 中国药科大学 一种新型抗肿瘤转移多肽及其应用
KR102860185B1 (ko) * 2022-01-26 2025-09-17 서울대학교병원 알데하이드 탈수소효소 2 조절을 통한 탈모의 예방, 개선, 또는 치료를 위한 병용요법
CN115772526B (zh) * 2022-07-20 2025-01-24 西北农林科技大学 西瓜ClmiR159-3P及其前体基因的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222551A1 (en) 1995-06-07 1996-12-19 Akzo Nobel Nv Tumor associated epitopes
GB9924060D0 (en) 1999-10-11 1999-12-15 Chiron Spa VIP54 protein
JP2002051785A (ja) * 2000-08-09 2002-02-19 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体ＣＬＮ−ＩｇＧによって認識される抗原エピトープのアミノ酸配列およびそれをコードするＤＮＡヌクレオチド配列
WO2002034287A2 (en) * 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
GB0102145D0 (en) 2001-01-26 2001-03-14 Scancell Ltd Substances
US20030138425A1 (en) 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
JP2005523888A (ja) * 2002-01-03 2005-08-11 ザ スクリプス リサーチ インスティテュート 癌関連エピトープ
CA2478930A1 (en) 2002-04-01 2003-10-16 Euro-Celtique, S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
JP2006518982A (ja) * 2002-10-02 2006-08-24 エフ．ホフマン−ラ　ロシュ　アーゲー Ｍｈｃｉｉ結合ペプチド
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
JP2007515924A (ja) 2003-12-15 2007-06-21 アウレリウム バイオファーマ インク． ビメンチン指向性診断法、および、多剤耐性を示す腫瘍性疾患の治療法
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
DE102005029845B4 (de) 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen
CN1712964A (zh) * 2005-07-18 2005-12-28 山东省医药生物技术研究中心 类风湿性关节炎特异性抗原性标志物及其应用
WO2007072221A2 (en) 2005-11-10 2007-06-28 Aurelium Biopharma Inc. Surface marker-directed cancer therapeutics
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
EA200801847A1 (ru) * 2006-02-17 2009-02-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ
WO2007098093A2 (en) * 2006-02-17 2007-08-30 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma
BRPI0710884A2 (pt) * 2006-04-24 2011-08-16 Shantha West, Inc. polipeptìdeo isolado, ácido nucléico, célula transformada, vetor, composição farmacêutica, kit, e, métodos para identificar uma célula que expressa um polipeptìdeo, de triagem para um distúrbio proliferativo da célula, para induzir ou aumentar uma resposta imune a um polipeptìdeo, para tratar um indivìduo tendo, ou em risco de ter, um tumor, para identificar um inibidor ou estimulador da expressão de um polipeptìdeo, e para triar um indivìduo tendo, ou em risco de ter, um distúrbio proliferativo da célula
DE602006013809D1 (de) * 2006-07-24 2010-06-02 Facultad De Medicina Universid Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
JP2011514322A (ja) * 2008-02-08 2011-05-06 ザ スクリプス リサーチ インスティチュート 遺伝的にコードされる非天然アミノ酸による免疫寛容解除
WO2010117694A2 (en) * 2009-03-30 2010-10-14 Prometheus Laboratories Inc. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2012095849A1 (en) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
WO2012103365A1 (en) 2011-01-28 2012-08-02 Oregon Health & Science University Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
ES2777502T3 (es) 2011-04-05 2020-08-05 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev Novedosos péptidos y su uso en diagnóstico y tratamiento
US20120295292A1 (en) * 2011-05-19 2012-11-22 University Of South Carolina Detecting Protein Arginine Deiminase (PAD) Activity in Human Tissues and Sera
JP6040228B2 (ja) 2011-05-27 2016-12-07 ノルディック・ビオサイエンス・エー／エスＮｏｒｄｉｃ Ｂｉｏｓｃｉｅｎｃｅ Ａ／Ｓ 診断用ペプチドの検出
US20130274125A1 (en) * 2012-04-16 2013-10-17 Bio-Rad Laboratories Inc. Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes

Also Published As

Publication number Publication date
EP2883054A2 (en) 2015-06-17
SG10201701001VA (en) 2017-05-30
PL3301447T3 (pl) 2021-09-06
GB201214007D0 (en) 2012-09-19
WO2014023957A2 (en) 2014-02-13
KR20150040314A (ko) 2015-04-14
CA2874515A1 (en) 2014-02-13
WO2014023957A3 (en) 2014-05-15
JP2018197236A (ja) 2018-12-13
ES2833962T3 (es) 2021-06-16
AU2013301341A1 (en) 2014-12-18
BR112015002574A2 (pt) 2017-11-07
CN107043414A (zh) 2017-08-15
US10233220B2 (en) 2019-03-19
PT2883054T (pt) 2018-10-15
EP2883054B1 (en) 2018-06-13
US20230192790A1 (en) 2023-06-22
KR102203096B1 (ko) 2021-01-14
EP3287787B1 (en) 2020-09-23
JP6490581B2 (ja) 2019-03-27
ES2681973T3 (es) 2018-09-17
US20150232525A1 (en) 2015-08-20
AU2013301341B2 (en) 2018-09-20
ES2843777T3 (es) 2021-07-20
IN2014DN10629A (da) 2015-09-11
PT3287787T (pt) 2020-11-26
CN104823054A (zh) 2015-08-05
CN104823054B (zh) 2019-03-26
PT3301447T (pt) 2021-02-18
EP3287787A1 (en) 2018-02-28
SG11201407804RA (en) 2015-02-27
US20180346537A1 (en) 2018-12-06
DK2883054T3 (da) 2018-09-17
EP3301447A1 (en) 2018-04-04
JP2015525569A (ja) 2015-09-07
HK1206427A1 (en) 2016-01-08
EP3301447B1 (en) 2020-12-02
BR112015002574A8 (pt) 2018-01-23
US12258377B2 (en) 2025-03-25
PL3287787T3 (pl) 2021-06-14
US20210198334A1 (en) 2021-07-01
DK3287787T3 (da) 2020-12-21
ZA201409095B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
DK3301447T3 (da) Anti-tumorrespons til modificerede selvepitoper
SMT201700065B (it) Derivato piridonico
DK3354728T3 (da) Alpha-amylase-varianter
DK4389885T3 (da) Alfa-amylasevarianter
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2824794A4 (en) Charging cable
EP2805877A4 (en) UNDER HOOD
DE112012006109A5 (de) Okklusionsschienenanordnung
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
DK2854722T3 (da) Stomipose
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
DK2825157T3 (da) Aminosyrelipider
EP2809729A4 (en) Siloxane polyether copolymers
CL2014002030A1 (es) Alfa-amilasa
DE112012006214T8 (de) Wulstringwickler
DK2831122T3 (da) Anthocyanidin-kompleks
DK2885638T3 (da) Molekylenet
DE112012005566T8 (de) Seltenerdnanoverbundmagnet
FI9831U1 (fi) Aurinkosuojan kiinnike
EP2873660A4 (en) INDOLCARBOXAMIDDERIVAT